Situación y perspectivas de las economías industrializadas, 1992-93

Incluye Bibliografía

Perfil motor de escolares sobrepesos e obesos de ambos os sexo na faixa etária de 9 e 10 anos

Pós-graduação em Pediatria - FMB

Influência do exercício físico resistido no metabolismo da próstata de ratos UChB (bebedor voluntário de etanol a 10%)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Níveis de mercúrio, prolactina e interleucina 10 em mulheres em idade reprodutiva e puérperas dos municípios de Itaituba e Ananindeua, Pará

Ao mercúrio tem sido atribuída a capacidade de interferir nos sistemas orgânicos imunológico e hormonal, além dos sistemas nervoso e renal frequentemente atingidos por esse agente tóxico. Mulheres em idade fértil ou grávidas constituem um grupo vulnerável a esses efeitos, em relação a si mesmas e seus conceptos. Foi avaliada a exposição ao mercúrio (Hg) e os níveis de prolactina (PRL) e interleucina-10 (IL-10) em 144 mulheres (no pós-parto e cerca de um ano depois) de Itaituba, área sob impacto ambiental do mercúrio e em mulheres de municípios da área metropolitana de Belém, sobretudo Ananindeua, área sem impacto conhecido do mercúrio (156 puérperas e 156 não puérperas). As análises de mercúrio total (Hg-t) em sangue foram feitas por Espectrometria de Absorção Atômica por Vapor Frio. As análises séricas de PRL foram feitas por Ensaio Imunoenzimático com detecção final em fluorescência e as determinações de IL-10 foram realizadas por Ensaio Imunoenzimático de Fase Sólida. Dados demográficos e epidemiológicos foram obtidos através de questionário semi-estruturado. As puérperas de Itaituba apresentaram média de Hg-t, PRL e IL-10 de 13,93 μg/l, 276,20 ng/ml e 39,54 pg/ml, respectivamente. Nas puérperas de Ananindeua as respectivas médias foram 3,67 μg/l, 337,70 ng/ml e 4,90 pg/ml. As mulheres não puérperas de Itaituba apresentaram média de Hg-t de 12,68 μg/l, média de PRL de 30,75 ng/ml e média de IL-10 de 14,20 pg/ml. As médias de Hg-t, PRL e IL-10 das mulheres de Ananindeua foram 2,73 μg/l, 17,07 ng/ml e 1,49 pg/ml, respectivamente. Os níveis de Hg-t, PRL e IL-10 foram maiores em Itaituba (p<0,0001), exceto em relação à PRL das puérperas, maior em Ananindeua. Os níveis semelhantes de Hg-t nas duas avaliações das mulheres de Itaituba (p=0,7056) e a correlação moderada sugerem continuidade da exposição (r=0,4736, p<0,0001). A principal variável preditora dos níveis de mercúrio foi o consumo de peixe nos modelos de regressão múltipla linear e logística. A paridade e os níveis de IL-10 apresentaram associação positiva com a PRL nas puérperas de Itaituba e o peso do recém-nascido e a IL-10, associação positiva com a PRL em puérperas de Ananindeua. A IL-10 apresentou associação negativa com a PRL nas mulheres não puérperas de Itaituba (p=0,0270) e positiva nas mulheres de Ananindeua (p=0,0266). Os níveis de Hg-t estavam associados negativamente com a PRL nas puérperas (p=0,0460) e positivamente com o trabalho em garimpo (p=0,0173) (este também importante para as não puérperas) em Itaituba, segundo os modelos logísticos. A IL-10 esteve associada positivamente à morbidade recente nas puérperas de Itaituba (p=0,0210), negativamente ao consumo de bebida alcoólica (p=0,0178) e positivamente ao trabalho em garimpo nas mulheres não puérperas (p=0,0199). A exposição crônica ao Hg das mulheres de Itaituba, a diferença nos níveis dos fatores imunoendócrinos avaliados em relação às mulheres não expostas e a associação com variáveis epidemiológicas relevantes, sugerem a possibilidade de impactos da exposição no perfil imunoendócrino das mulheres de Itaituba, chamando atenção para a importância da vigilância da saúde dessa população e o possível uso de bioindicadores como a PRL em sua avaliação.

Polimorfismos de nucleotídeo único (SNPs) nos genes codificadores da IL-10, TNF-α e em NFkB1 e sua associação com parâmetros clínicos, laboratoriais e de seguimento de pacientes com linfoma de Hodgkin clássico

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Polimorfismos de nucleotídeo único (SNPs) nos genes codificadores da IL-10, TNF-α e em NFkB1 e sua associação com parâmetros clínicos, laboratoriais e de seguimento de pacientes com linfoma de Hodgkin clássico

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

The antioxidant response of the liver of male Swiss mice raised on a AIN 93 or commercial diet

Background: Reactive oxygen species (ROS) are formed under natural physiological conditions and are thought to play an important role in many human diseases. A wide range of antioxidants are involved in cellular defense mechanisms against ROS, which can be generated in excess during stressful conditions, these include enzymes and non-enzymatic antioxidants. The aim of this study was to evaluate the antioxidant responses of mice to two diets control, commercial and the purified AIN 93 diet, commonly used in experiments with rodents. Results: Malondialdehyde (MDA) and hydrogen peroxide (H2O2) concentrations and superoxide dismutase (SOD) and glutathione reductase (GR) activities determined in the liver were lower in the group of mice fed with the AIN 93 diet, while catalase (CAT) activity was higher in the same group, when compared to the group fed on the commercial diet. Liver glutathione peroxidase (GSH-Px) activity was similar in the groups fed on either AIN 93 or the commercial diets. Two SOD isoforms, Mn-SODII and a Cu/Zn-SODV, were specifically reduced in the liver of the AIN 93 diet fed animals. Conclusions: The clear differences in antioxidant responses observed in the livers of mice fed on the two diets suggest that the macro- and micro-nutrient components with antioxidant properties, including vitamin E, can promote changes in the activity of enzymes involved in the removal of the ROS generated by cell metabolism.

Natural variations at position 93 of the invariant Vα24-Jα18 α chain of human iNKT-cell TCRs strongly impact on CD1d binding

Human invariant natural killer T (NKT) cell TCRs bind to CD1d via an "invariant" Vα24-Jα18 chain (iNKTα) paired to semi-invariant Vβ11 chains (iNKTβ). Single-amino acid variations at position 93 (p93) of iNKTα, immediately upstream of the "invariant" CDR3α region, have been reported in a substantial proportion of human iNKT-cell clones (4-30%). Although p93, a serine in most human iNKT-cell TCRs, makes no contact with CD1d, it could affect CD1d binding by altering the conformation of the crucial CDR3α loop. By generating recombinant refolded iNKT-cell TCRs, we show that natural single-nucleotide variations in iNKTα, translating to serine, threonine, asparagine or isoleucine at p93, exert a powerful effect on CD1d binding, with up to 28-fold differences in affinity between these variants. This effect was observed with CD1d loaded with either the artificial α-galactosylceramide antigens KRN7000 or OCH, or the endogenous glycolipid β-galactosylceramide, and its importance for autoreactive recognition of endogenous lipids was demonstrated by the binding of variant iNKT-cell TCR tetramers to cell surface expressed CD1d. The serine-containing variant showed the strongest CD1d binding, offering an explanation for its predominance in vivo. Complementary molecular dynamics modeling studies were consistent with an impact of p93 on the conformation of the CDR3α loop.

Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93

PURPOSE: The value of adjuvant tamoxifen after chemotherapy for premenopausal women with breast cancer has not been adequately assessed. PATIENTS AND METHODS: Between 1993 and 1999, International Breast Cancer Study Group Trial 13-93 enrolled 1,246 assessable premenopausal women with axillary node-positive, operable breast cancer. All patients received chemotherapy (cyclophosphamide plus either doxorubicin or epirubicin for four courses followed by immediate or delayed classical cyclophosphamide, methotrexate, and fluorouracil for three courses), which was followed by either tamoxifen (20 mg daily) for 5 years or no further treatment. The primary end point was disease-free survival (DFS). Tumors were classified as estrogen receptor (ER) -positive (n = 735, 59%) if immunohistochemical (IHC) or ligand-binding assays (LBA) were clearly positive. The ER-negative group included all other tumors (n = 511, 41%). A subset of the ER-negative group was defined as ER absent (n = 108, 9%) if IHC staining was none or if the LBA result was 0 fmol/mg cytosol protein. The median follow-up time was 7 years. RESULTS: Tamoxifen improved DFS in the ER-positive cohort (hazard ratio [HR] for tamoxifen v no tamoxifen = 0.59; 95% CI, 0.46 to 0.75; P < .0001) but not in the ER-negative cohort (HR = 1.02; 95% CI, 0.77 to 1.35; P = .89). Tamoxifen had a detrimental effect on patients with ER-absent tumors compared with no tamoxifen in an unplanned exploratory analysis (HR = 2.10; 95% CI, 1.03 to 4.29; P = .04). Patients with ER-positive tumors who achieved chemotherapy-induced amenorrhea had a significantly improved outcome (HR for amenorrhea v no amenorrhea = 0.61; 95% CI, 0.44 to 0.86; P = .004), whether or not they received tamoxifen. CONCLUSION: Tamoxifen after adjuvant chemotherapy significantly improved treatment outcome in premenopausal patients with endocrine-responsive disease, but its use as adjuvant therapy for patients with ER-negative tumors is not recommended.

Two-year outcome with Nobel Direct implants: a retrospective radiographic and microbiologic study in 10 patients

INTRODUCTION: The Nobel Direct implant (Nobel Biocare AB, Göteborg, Sweden) was developed to minimize marginal bone resorption and to result in "soft tissue integration" for an optimized aesthetic outcome. However, conflicting results have been presented in the literature. The aim of this present study was to evaluate the clinical and microbiologic outcomes of Nobel Direct implants. MATERIALS AND METHODS: Ten partially edentulous subjects without evidence of active periodontitis (mean age 55 years) received 12 Nobel Direct implants. Implants were loaded with single crowns after a healing period of 3 to 6 months. Treatment outcomes were assessed at month 24. Routine clinical assessments, intraoral radiographs, and microbiologic samplings were made. Histologic analysis of one failing implant and chemical spectroscopy around three unused implants was performed. Paired Wilcoxon signed-rank test was used for the evaluation of bone loss; otherwise, descriptive analysis was performed. RESULTS: Implants were functionally loaded after 3 to 6 months. At 2 years, the mean bone loss of remaining implants was 2.0 mm (SD +/- 1.1 mm; range: 0.0-3.4 mm). Three out of 12 implants with an early mean bone loss >3 mm were lost. The surviving implants showed increasing bone loss between 6 and 24 months (p = .028). Only 3 out of the 12 implants were considered successful and showed bone loss of <1.7 mm after 2 years. High rates of pathogens, including Aggregatibacter actinomycetemcomitans, Fusobacterium spp., Porphyromonas gingivalis, Pseudomonas aeruginosa, and Tanerella forsythia, were found. Chemical spectroscopy revealed, despite the normal signals from Ti, O, and C, also peaks of P, F, S, N, and Ca. A normal histologic image of osseointegration was observed in the apical part of the retrieved implant. CONCLUSION: Radiographic evidence and 25% implant failures are indications of a low success rate. High counts and prevalence of significant pathogens were found at surviving implants. Although extensive bone loss had occurred in the coronal part, the apical portion of the implant showed some bone to implant integration.

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrine-responsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high.